No Data
Citi Keeps Their Hold Rating on Merck & Company (MRK)
Merck Says It Will Host HIV Research Pipeline Investor Event On July 17, 2025, Highlighting Advances In Treatment And Prevention
Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $99
Merck's Pulmonary Arterial Hypertension Drug Meets Primary Endpoint
Express News | Merck: The innovative CMV prevention drug Prevymis in two formulations has been approved for use in pediatric patients within China.
